Practical guide to the meta-analysis of rare events

Evidence-Based Mental Health

Volumn 21, Issue 2, 2018, Pages 72-76

  Efthimiou, Orestis ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APPENDIX; ARTICLE; ATTENTION; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; MENTAL HEALTH; META ANALYSIS; OUTCOME ASSESSMENT; SCIENTIST; SENSITIVITY ANALYSIS; SOFTWARE; META ANALYSIS (TOPIC); PROCEDURES; STATISTICAL MODEL;

NEUROLEPTIC AGENT;

ANTIPSYCHOTIC AGENTS; HUMANS; META-ANALYSIS AS TOPIC; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 85046625982     PISSN: 13620347     EISSN: None     Source Type: Journal    
DOI: 10.1136/eb-2018-102911     Document Type: Article

References (30)

1. Higgins J, Deeks JJ, Atman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5. 1. 0 (updated March 2011): The Cochrane Collaboration, 2011. www. cochrane-handbook. org
2. Vandermeer B, Bialy L, Hooton N, et al. Meta-analyses of safety data: a comparison of exact versus asymptotic methods. Stat Methods Med Res 2009;18:421-32.
3. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
4. Nikolakopoulou A, Mavridis D, Salanti G. Demystifying fixed and random effects meta-analysis. Evid Based Ment Health 2014;17:53-7.
5. Bradburn MJ, Deeks JJ, Berlin JA, et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007;26:53-77.
6. Keus F, Wetterslev J, Gluud C, et al. Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials. Am J Gastroenterol 2009;104:546-51.
7. Kuss O. Statistical methods for meta-analyses including information from studies without any events-add nothing to nothing and succeed nevertheless. Stat Med 2015;34:1097-116.
8. Bhaumik DK, Amatya A, Normand SL, et al. Meta-Analysis of Rare Binary Adverse Event Data. J Am Stat Assoc 2012;107:555-67.
9. Kishi T, Matsunaga S, Iwata N. Mortality risk associated with long-acting injectable antipsychotics: a systematic review and meta-analyses of randomized controlled trials. Schizophr Bull 2016;42:1438-45.
10. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.
11. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004;23:1351-75.
12. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
13. Jaynes ET. Bayesian Methods: General Background, 1986.
14. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 2001;10:277-303.
15. Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med 1995;14:2685-99.
16. Stijnen T, Hamza TH, Ozdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med 2010;29:3046-67.
17. Lambert PC, Sutton AJ, Burton PR, et al. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med 2005;24:2401-28.
18. Turner RM, Davey J, Clarke MJ, et al. Predicting the extent of heterogeneity in metaanalysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol 2012;41:818-27.
19. Turner RM, Jackson D, Wei Y, et al. Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis. Stat Med 2015;34:984-98.
20. Chen Y, Chu H, Luo S, et al. Bayesian analysis on meta-analysis of casecontrol studies accounting for within-study correlation. Stat Methods Med Res 2015;24:836-55.
21. Rücker G, Schwarzer G, Carpenter J, et al. Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells. Stat Med 2009;28:721-38.
22. Tian L, Cai T, Pfeffer MA, et al. Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction. Biostatistics 2009;10:275-81.
23. Cai T, Parast L, Ryan L. Meta-analysis for rare events. Stat Med 2010;29:2078-89.
24. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014.
25. Lunn D, Spiegelhalter D, Thomas A, et al. The BUGS project: evolution, critique and future directions. Stat Med 2009;28:3049-67.
26. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
27. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007;147:578-81.
28. Lane PW. Meta-analysis of incidence of rare events. Stat Methods Med Res 2013;22:117-32.
29. Wasserstein RL, Lazar NA. The ASA's statement on p-Values: context, process, and purpose. Am Stat 2016;70:129-33.
30. Benjamin DJ, Berger JO, Johannesson M, et al. Redefine statistical significance. Nature Human Behaviour 2017;1.